Apathy and Anhedonia Rating Scales in Parkinson's Disease : Critique and Recommendations
Identifieur interne : 001365 ( PascalFrancis/Checkpoint ); précédent : 001364; suivant : 001366Apathy and Anhedonia Rating Scales in Parkinson's Disease : Critique and Recommendations
Auteurs : Albert F. G. Leentjens [Pays-Bas] ; Kathy Dujardin [France] ; Laura Marsh [États-Unis] ; Pablo Martinez-Martin [Espagne] ; Irene H. Richard [États-Unis] ; Sergio E. Starkstein [Australie] ; Daniel Weintraub [États-Unis] ; Cristina Sampaio [Portugal] ; Wemer Poewe [Autriche] ; Olivier Rascol [France] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis]Source :
- Movement disorders [ 0885-3185 ] ; 2008.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Recommandation.
English descriptors
- KwdEn :
Abstract
Apathy is a common condition in Parkinson's disease (PD) and is generally defined as a lack of motivation. It is associated with more severe cognitive dysfunction and a decrease in activities of daily living (ADL) performance. Anhedonia, the inability to experience pleasure, can be a symptom of both depressive and apathetic syndromes. The Movement Disorder Society (MDS) commissioned a task force to assess the clinimetric properties of apathy and anhedonia scales in PD patients. A systematic literature review was conducted to identify scales that have either been validated or used in PD patients. Apathy scales identified for review include the Apathy Evaluation Scale (AES), the Apathy Scale (AS), the Apathy Inventory (Al), and the Lille Apathy Rating Scale (LARS). In addition, item 4 (motivation/initiative) of the Unified Parkinson's Disease Rating Scale (UPDRS) and item 7 (apathy) of the Neuropsychiatric Inventory (NPI) were included. Anhedonia scales identified for review were the Snaith-Hamilton Pleasure Scale (SHAPS) and the Chapman scales for physical and social anhedonia. Only the AS is classified as "recommended" to assess apathy in PD. Although item 4 of the UPDRS also meets the criteria to be classified as recommended, it should be considered for screening only because of the obvious limitations of a single item construct. For the assessment of anhedonia, only the SHAPS meets the criteria of "Suggested." Information on the validity of apathy and anhedonia scales is limited because of the lack of consensus on diagnostic criteria for these conditions.
Affiliations:
- Australie, Autriche, Espagne, France, Pays-Bas, Portugal, États-Unis
- Communauté de Madrid, Géorgie (États-Unis), Illinois, Maryland, Midi-Pyrénées, Pennsylvanie, État de New York
- Lille, Madrid, Toulouse
- Université Toulouse III - Paul Sabatier, Université de Toulouse
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:08-0536677Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Apathy and Anhedonia Rating Scales in Parkinson's Disease : Critique and Recommendations</title><author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Hospital</s1><s2>Maastricht</s2><s3>NLD</s3><sZ>1 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>Maastricht</wicri:noRegion></affiliation></author><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Psychiatry, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Nertroepidemology Unit, National Centre for Epidemiology, Carlos 111 Institute of Health</s1><s2>Madrid</s2><s3>ESP</s3><sZ>4 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name><affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="07"><s1>Department of Psychiatry, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>school of Psychiatry, University of Western Australia and Fremantle Hospital</s1><s2>Fremantle, Western Australia</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Fremantle, Western Australia</wicri:noRegion></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation wicri:level="2"><inist:fA14 i1="09"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1><s2>Philadelphia, Pennsylvania</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</s1><s3>PRT</s3><sZ>8 aut.</sZ></inist:fA14><country>Portugal</country><wicri:noRegion>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</wicri:noRegion></affiliation></author><author><name sortKey="Poewe, Wemer" sort="Poewe, Wemer" uniqKey="Poewe W" first="Wemer" last="Poewe">Wemer Poewe</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Neurology. University Hospital</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>9 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>Department of Neurology. University Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Laboratoire de Pharmacologie Medicate et Clinique</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation wicri:level="2"><inist:fA14 i1="13"><s1>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine</s1><s2>Atlanta, Georgia</s2><s3>USA</s3><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="2"><inist:fA14 i1="14"><s1>Department of Neurological Services, Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">08-0536677</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 08-0536677 INIST</idno><idno type="RBID">Pascal:08-0536677</idno><idno type="wicri:Area/PascalFrancis/Corpus">001064</idno><idno type="wicri:Area/PascalFrancis/Curation">001C55</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001365</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Apathy and Anhedonia Rating Scales in Parkinson's Disease : Critique and Recommendations</title><author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Hospital</s1><s2>Maastricht</s2><s3>NLD</s3><sZ>1 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>Maastricht</wicri:noRegion></affiliation></author><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Psychiatry, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Nertroepidemology Unit, National Centre for Epidemiology, Carlos 111 Institute of Health</s1><s2>Madrid</s2><s3>ESP</s3><sZ>4 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name><affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="07"><s1>Department of Psychiatry, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>school of Psychiatry, University of Western Australia and Fremantle Hospital</s1><s2>Fremantle, Western Australia</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Fremantle, Western Australia</wicri:noRegion></affiliation></author><author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name><affiliation wicri:level="2"><inist:fA14 i1="09"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1><s2>Philadelphia, Pennsylvania</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</s1><s3>PRT</s3><sZ>8 aut.</sZ></inist:fA14><country>Portugal</country><wicri:noRegion>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</wicri:noRegion></affiliation></author><author><name sortKey="Poewe, Wemer" sort="Poewe, Wemer" uniqKey="Poewe W" first="Wemer" last="Poewe">Wemer Poewe</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Department of Neurology. University Hospital</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>9 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>Department of Neurology. University Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Laboratoire de Pharmacologie Medicate et Clinique</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation wicri:level="2"><inist:fA14 i1="13"><s1>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine</s1><s2>Atlanta, Georgia</s2><s3>USA</s3><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="2"><inist:fA14 i1="14"><s1>Department of Neurological Services, Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anhedonia</term><term>Apathy</term><term>Depression</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Psychometrics</term><term>Recommendation</term><term>Reliability</term><term>Validity</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term><term>Etat dépressif</term><term>Pathologie du système nerveux</term><term>Anhédonie</term><term>Recommandation</term><term>Psychométrie</term><term>Validité</term><term>Fiabilité</term><term>Apathie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Recommandation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Apathy is a common condition in Parkinson's disease (PD) and is generally defined as a lack of motivation. It is associated with more severe cognitive dysfunction and a decrease in activities of daily living (ADL) performance. Anhedonia, the inability to experience pleasure, can be a symptom of both depressive and apathetic syndromes. The Movement Disorder Society (MDS) commissioned a task force to assess the clinimetric properties of apathy and anhedonia scales in PD patients. A systematic literature review was conducted to identify scales that have either been validated or used in PD patients. Apathy scales identified for review include the Apathy Evaluation Scale (AES), the Apathy Scale (AS), the Apathy Inventory (Al), and the Lille Apathy Rating Scale (LARS). In addition, item 4 (motivation/initiative) of the Unified Parkinson's Disease Rating Scale (UPDRS) and item 7 (apathy) of the Neuropsychiatric Inventory (NPI) were included. Anhedonia scales identified for review were the Snaith-Hamilton Pleasure Scale (SHAPS) and the Chapman scales for physical and social anhedonia. Only the AS is classified as "recommended" to assess apathy in PD. Although item 4 of the UPDRS also meets the criteria to be classified as recommended, it should be considered for screening only because of the obvious limitations of a single item construct. For the assessment of anhedonia, only the SHAPS meets the criteria of "Suggested." Information on the validity of apathy and anhedonia scales is limited because of the lack of consensus on diagnostic criteria for these conditions.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>23</s2></fA05><fA06><s2>14</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Apathy and Anhedonia Rating Scales in Parkinson's Disease : Critique and Recommendations</s1></fA08><fA11 i1="01" i2="1"><s1>LEENTJENS (Albert F. G.)</s1></fA11><fA11 i1="02" i2="1"><s1>DUJARDIN (Kathy)</s1></fA11><fA11 i1="03" i2="1"><s1>MARSH (Laura)</s1></fA11><fA11 i1="04" i2="1"><s1>MARTINEZ-MARTIN (Pablo)</s1></fA11><fA11 i1="05" i2="1"><s1>RICHARD (Irene H.)</s1></fA11><fA11 i1="06" i2="1"><s1>STARKSTEIN (Sergio E.)</s1></fA11><fA11 i1="07" i2="1"><s1>WEINTRAUB (Daniel)</s1></fA11><fA11 i1="08" i2="1"><s1>SAMPAIO (Cristina)</s1></fA11><fA11 i1="09" i2="1"><s1>POEWE (Wemer)</s1></fA11><fA11 i1="10" i2="1"><s1>RASCOL (Oliver)</s1></fA11><fA11 i1="11" i2="1"><s1>STEBBINS (Glenn T.)</s1></fA11><fA11 i1="12" i2="1"><s1>GOETZ (Christopher G.)</s1></fA11><fA14 i1="01"><s1>Department of Psychiatry, Maastricht University Hospital</s1><s2>Maastricht</s2><s3>NLD</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Neurology and Movement Disorders Unit, Lille University Hospital</s1><s2>Lille</s2><s3>FRA</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Psychiatry, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="05"><s1>Nertroepidemology Unit, National Centre for Epidemiology, Carlos 111 Institute of Health</s1><s2>Madrid</s2><s3>ESP</s3><sZ>4 aut.</sZ></fA14><fA14 i1="06"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="07"><s1>Department of Psychiatry, University of Rochester School of Medicine and Dentistry</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="08"><s1>school of Psychiatry, University of Western Australia and Fremantle Hospital</s1><s2>Fremantle, Western Australia</s2><s3>AUS</s3><sZ>6 aut.</sZ></fA14><fA14 i1="09"><s1>Department of Psychiatry, University of Pennsylvania School of Medicine</s1><s2>Philadelphia, Pennsylvania</s2><s3>USA</s3><sZ>7 aut.</sZ></fA14><fA14 i1="10"><s1>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine</s1><s3>PRT</s3><sZ>8 aut.</sZ></fA14><fA14 i1="11"><s1>Department of Neurology. University Hospital</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>9 aut.</sZ></fA14><fA14 i1="12"><s1>Laboratoire de Pharmacologie Medicate et Clinique</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>10 aut.</sZ></fA14><fA14 i1="13"><s1>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine</s1><s2>Atlanta, Georgia</s2><s3>USA</s3><sZ>11 aut.</sZ></fA14><fA14 i1="14"><s1>Department of Neurological Services, Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>12 aut.</sZ></fA14><fA20><s1>2004-2014</s1></fA20><fA21><s1>2008</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000184512460080</s5></fA43><fA44><s0>0000</s0><s1>© 2008 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>40 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>08-0536677</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Apathy is a common condition in Parkinson's disease (PD) and is generally defined as a lack of motivation. It is associated with more severe cognitive dysfunction and a decrease in activities of daily living (ADL) performance. Anhedonia, the inability to experience pleasure, can be a symptom of both depressive and apathetic syndromes. The Movement Disorder Society (MDS) commissioned a task force to assess the clinimetric properties of apathy and anhedonia scales in PD patients. A systematic literature review was conducted to identify scales that have either been validated or used in PD patients. Apathy scales identified for review include the Apathy Evaluation Scale (AES), the Apathy Scale (AS), the Apathy Inventory (Al), and the Lille Apathy Rating Scale (LARS). In addition, item 4 (motivation/initiative) of the Unified Parkinson's Disease Rating Scale (UPDRS) and item 7 (apathy) of the Neuropsychiatric Inventory (NPI) were included. Anhedonia scales identified for review were the Snaith-Hamilton Pleasure Scale (SHAPS) and the Chapman scales for physical and social anhedonia. Only the AS is classified as "recommended" to assess apathy in PD. Although item 4 of the UPDRS also meets the criteria to be classified as recommended, it should be considered for screening only because of the obvious limitations of a single item construct. For the assessment of anhedonia, only the SHAPS meets the criteria of "Suggested." Information on the validity of apathy and anhedonia scales is limited because of the lack of consensus on diagnostic criteria for these conditions.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Etat dépressif</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Depression</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Estado depresivo</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Anhédonie</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Anhedonia</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Anhedonia</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Recommandation</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Recommendation</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Recomendación</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Psychométrie</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Psychometrics</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Psicometría</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Validité</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Validity</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Validez</s0><s5>12</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Fiabilité</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Reliability</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Fiabilidad</s0><s5>13</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Apathie</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Apathy</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Apatía</s0><s4>CD</s4><s5>96</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Trouble de l'humeur</s0><s5>42</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Mood disorder</s0><s5>42</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Trastorno humor</s0><s5>42</s5></fC07><fN21><s1>350</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Australie</li><li>Autriche</li><li>Espagne</li><li>France</li><li>Pays-Bas</li><li>Portugal</li><li>États-Unis</li></country><region><li>Communauté de Madrid</li><li>Géorgie (États-Unis)</li><li>Illinois</li><li>Maryland</li><li>Midi-Pyrénées</li><li>Pennsylvanie</li><li>État de New York</li></region><settlement><li>Lille</li><li>Madrid</li><li>Toulouse</li></settlement><orgName><li>Université Toulouse III - Paul Sabatier</li><li>Université de Toulouse</li></orgName></list><tree><country name="Pays-Bas"><noRegion><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name></noRegion></country><country name="France"><noRegion><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name></noRegion><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Olivier Rascol</name></country><country name="États-Unis"><region name="Maryland"><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name></region><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name></country><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name></region></country><country name="Australie"><noRegion><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name></noRegion></country><country name="Portugal"><noRegion><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name></noRegion></country><country name="Autriche"><noRegion><name sortKey="Poewe, Wemer" sort="Poewe, Wemer" uniqKey="Poewe W" first="Wemer" last="Poewe">Wemer Poewe</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001365 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 001365 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:08-0536677
|texte= Apathy and Anhedonia Rating Scales in Parkinson's Disease : Critique and Recommendations
}}
| This area was generated with Dilib version V0.6.23. |  |